Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Slides:

Advertisements

Similar presentations

Regulatory T cells & parasites: therapeutic potential

Advertisements

Figure 3 Low-grade inflammation in FGID

Figure 2 Exosome composition

Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 5 Dendritic cells in liver inflammation

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Patients cured of HCV infection

Figure 1 Gut microorganisms at the intersection of several diseases

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 2 The microbiome–gut–brain axis

Figure 7 Clinical options for HCC therapy

Figure 2 Main functions of IL-1

Figure 3 The T-cell cytokine tree in IBD

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Definition and concept of ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Overview of the immunopathogenesis of ulcerative colitis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Differentiation and functional control of T-cell subsets

Figure 4 Macrophages in liver inflammation

Figure 5 Hepatic regeneration in ACLF

Figure 1 Median coverage and distribution by

Warren Strober, Ivan J. Fuss Gastroenterology

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 2 Key brain–immune–gut interactions

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Three distinct paracellular epithelial

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Regulatory T cells and cancer: an undesired tolerance

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 1 Mucosal immune networks

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Translating Inflammatory Bowel Disease Research into Clinical Medicine

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 4 Bile-acid-induced TGR5 signalling pathways in macrophages

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients with IBD. Although IL-12-driven type 1 T helper (TH1) cells and IL-23-activated type 17 T helper (TH17) cells were detected in Crohn's disease, type 2 T helper (TH2), type 9 T helper (TH9) and TH17 cells were identified in ulcerative colitis. The key transcription factors for each T-cell subset as well as the subset associated signature cytokines are indicated. NK cell, natural killer cell; Treg cell, regulatory T cell. Neurath, M. F. (2016) Current and emerging therapeutic targets for IBD Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.208